Acadia Pharmaceuticals
ACAD
Market cap $3.73B

21.71 USD

-0.03

0.14%

At close Jun 13, 4:00 PM EDT

After hours

21.71

+0.00

0.00%

1 day

-0.14%

5 days

-2.65%

1 month

26.22%

3 months

29.38%

6 months

25.78%

Year to date

16.35%

1 year

43.87%

5 years

-53.30%

10 years

-44.42%

About: Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Employees: 654

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 11 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

426% more call options, than puts

Call options by funds: $30.3M | Put options by funds: $5.77M

66% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 38

7% more funds holding

Funds holding: 294 [Q4 2024] → 316 (+22) [Q1 2025]

4.82% more ownership

Funds ownership: 97.91% [Q4 2024] → 102.73% (+4.82%) [Q1 2025]

3% less repeat investments, than reductions

Existing positions increased: 99 | Existing positions reduced: 102

5% less capital invested

Capital invested by funds: $2.99B [Q4 2024] → $2.85B (-$143M) [Q1 2025]

40% less funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 3 (-2) [Q1 2025]

See Fund Rankings

Research analyst outlook

11 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$22

1%

upside

Avg. target

$28

27%

upside

High target

$35

61%

upside

11 analyst ratings

8 positive

73%

3 neutral

27%

0 negative

0%

JP Morgan Tessa Romero	38%upside $30	Overweight Maintained	6 Jun 2025
B of A Securities Tazeen Ahmad	6%upside $23	Neutral Maintained	5 Jun 2025
Deutsche Bank David Hoang	61%upside $35	Buy Upgraded	21 May 2025
Morgan Stanley Jeffrey Hung	11%upside $24	Equal-Weight Maintained	20 May 2025
Mizuho Uy Ear	6%upside $23	Neutral Maintained	19 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 11 articles about ACAD published over the past 30 days

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories Pvt. Ltd. and MSN Pharmaceuticals, Inc. In its affirmance, the Appeals Court applied the precedent est.

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Zacks Investment Research

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Why Is Acadia (ACAD) Up 26.1% Since Last Earnings Report?

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia's management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live webcast, please click here. A replay of Acadia's R&D Day will be available on the company'.

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording will be available on the website for approximately one month following the presentation. About Acadia P.

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role Allyson will be joining Acadia's commercial leadership team with a focus on maximizing the potential of DAYBUE® and preparing for future product launches as the Company expands its rare disease portfolio. “We are delighted to welcome Allyson to Acadia,” said Catherine Owen Adams, Chief Executive Offic.

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted inducement awards consisting of non-qualified stock options to purchase 64,252 shares of common stock and 56,277 restricted stock units (“RSUs”) to twenty-eight new employees under Acadia's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees'.

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

GSK or ACAD: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?

GSK or ACAD: Which Is the Better Value Stock Right Now?

Zacks Investment Research

ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent

Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.

ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday.

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Acadia Pharmaceuticals secured another court win on Nuplazid that solidifies its IP position and long-term exclusivity. The commercial business' performance remains slightly underwhelming but there are signs of stabilization and improved expectations. ACP-101 phase 3 results in Prader Willi syndrome patients are now expected in Q4 2025 and my data preview is available in this article.

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

See News Rankings

Charts implemented using Lightweight Charts™